Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/105591
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCombs, C.en
dc.contributor.authorSchuit, E.en
dc.contributor.authorCaritis, S.en
dc.contributor.authorLim, A.en
dc.contributor.authorGarite, T.en
dc.contributor.authorMaurel, K.en
dc.contributor.authorRouse, D.en
dc.contributor.authorThom, E.en
dc.contributor.authorTita, A.en
dc.contributor.authorMol, B.en
dc.date.issued2016en
dc.identifier.citationBJOG: an International Journal of Obstetrics and Gynaecology, 2016; 123(5):682-690en
dc.identifier.issn1470-0328en
dc.identifier.issn1471-0528en
dc.identifier.urihttp://hdl.handle.net/2440/105591-
dc.description.abstractPreterm birth complicates almost all triplet pregnancies and no preventive strategy has proven effective.To determine, using individual patient data (IPD) meta-analysis, whether the outcome of triplet pregnancy is affected by prophylactic administration of 17-hydroxyprogesterone caproate (17OHPc).We searched literature databases, trial registries and references in published articles.Randomised controlled trials (RCTs) of progestogens versus control that included women with triplet pregnancies.Investigators from identified RCTs collaborated on the protocol and contributed their IPD. The primary outcome was a composite measure of adverse perinatal outcome. The secondary outcome was the rate of birth before 32 weeks of gestation. Other pre-specified outcomes included randomisation-to-delivery interval and rates of birth at <24, <28 and <34 weeks of gestation.Three RCTs of 17OHPc versus placebo included 232 mothers with triplet pregnancies and their 696 offspring. Risk-of-bias scores and between-study heterogeneity were low. Baseline characteristics were comparable between 17OHPc and placebo groups. The rate of the composite adverse perinatal outcome was similar among those treated with 17OHPc and those treated with placebo (34 and 35%, respectively; risk ratio [RR] 0.98, 95% confidence interval [95% CI] 0.79-1.2). The rate of birth at <32 weeks was also similar in the two groups (35 and 38%, respectively; RR 0.92, 95% CI 0.55-1.56). There were no significant between-group differences in perinatal mortality rate, randomisation-to-delivery interval, or other specified outcomes.Prophylactic 17OHPc given to mothers with triplet pregnancies had no significant impact on perinatal outcome or pregnancy duration.17-Hydroxyprogesterone caproate had no significant impact on the outcome or duration of triplet pregnancy.en
dc.description.statementofresponsibilityC A Combs, E Schuit, S N Caritis, A C Lim, T J Garite, K Maurel, D Rouse, E Thom, A T Tita, B W J Mol, A Global Obstetrics Network (GONet) collaborationen
dc.language.isoenen
dc.publisherWiley-Blackwellen
dc.rights© 2015 Royal College of Obstetricians and Gynaecologistsen
dc.subject17-Hydroxyprogesterone caproate; multiple gestation; preterm birth prevention; progestogens; triplet pregnancyen
dc.title17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysisen
dc.typeJournal articleen
dc.identifier.rmid0030040504en
dc.identifier.doi10.1111/1471-0528.13779en
dc.identifier.pubid223815-
pubs.library.collectionObstetrics and Gynaecology publicationsen
pubs.library.teamDS10en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidMol, B. [0000-0001-8337-550X]en
Appears in Collections:Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.